A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing

Exclusion Criteria

• •Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the subject's last study related visit
• •Participation in any investigational drug trial within 30 days preceding the screening visit
• •A known hypersensitivity to albuterol or any of the excipients in the formulations.
• •History of severe milk protein allergy
• •History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, acute or chronic sinusitis, otitis media, influenza, etc) which is not resolved within 1 week prior to the Screening Visit.
• •Use of any protocol prohibited concomitant medications for asthma or any protocol prohibited concomitant non-asthma medications
• •Inability to tolerate or unwillingness to comply with the protocol requirements.
• •History of life-threatening asthma
• •Any asthma exacerbation within 3 months of the Screening Visit requiring oral or systemic corticosteroids
• •History of life-threatening asthma
• •Other criteria apply